DESTINY-Breast03 Phase 3 Study Results

Antitumor Responses 100 Change in target lesion from baseline (%) -50 0 50 50 -100 0 6 12 Data cutoff: November 15, 2021 ESMO BC 2022 #166 Mini Oral 18 Time (weeks) Daiichi-Sankyo Complete response Partial response Stable disease RECIST Progression New lesion Median follow-up: 3.9 months ◆ Median time to response was 1.4 mos. (95% CI, 1.35-1.58) ◆ All patients with a response had an ongoing response at data cutoff ◆ Median duration of response was not reached 24 30 50 36 36 Dotted lines indicate thresholds for partial response (-30%) and progressive disease (20%). 78

View entire presentation